ONGold Resources announced an updated Mineral Resource Estimate for its Monument Bay Gold Project in Manitoba, reporting 2 million ounces of gold classified as Measured and Indicated within an open-pit constrained resource. The estimate, effective July 31, 2026, also includes 0.49 million ounces in the Inferred category and is based on extensive geological modeling and 833 historical drill holes. The company plans a Phase I drilling program of about 11,150 meters to test higher-grade gold zones, particularly in the eastern deposit area, and is exploring tungsten as an additional critical mineral opportunity. This update marks a key milestone for ONGold as it advances the project with strong local and governmental support into 2027 and beyond.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
